Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.56 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | CRHBP | P24387 | 1/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27429824 | 0.79 | CYP2A6 (0.56) | CYP2A6CHRNA7SMN1; SMN2CRHBPCRHR2 | |
| SCHEMBL7068604 | 0.76 | CYP2A6 (0.62) | CYP2A6CHRNA7SMN1; SMN2CRHBPCRHR2 | |
| SCHEMBL2248829 | 0.72 | CYP2A6 (1.00) | CYP2A6CHRNA7SMN1; SMN2CRHBPCRHR2 | |
| SCHEMBL18666075 | 0.71 | CYP2A6 (0.67) | CYP2A6CHRNA7SMN1; SMN2CRHBPCRHR2 | |
| SCHEMBL655428 | 0.71 | CYP2A6 (1.00) | CYP2A6CHRNA7SMN1; SMN2CRHBPCRHR2 | |
| SCHEMBL16398945 | 0.71 | CYP2A6 (0.67) | CYP2A6CHRNA7SMN1; SMN2CRHBPCRHR2 | |
| SCHEMBL2537423 | 0.71 | CYP2A6 (0.67) | CYP2A6CHRNA7SMN1; SMN2CRHBPCRHR2 | |
| SCHEMBL3113993 | 0.71 | CYP2A6 (0.67) | CYP2A6CHRNA7SMN1; SMN2CRHBPCRHR2 | |
| SCHEMBL3106949 | 0.71 | CYP2A6 (0.70) | CYP2A6CHRNA7SMN1; SMN2CRHBPCRHR2 | |
| SCHEMBL91157 | 0.71 | CYP2A6 (0.67) | CYP2A6CHRNA7SMN1; SMN2CRHBPCRHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8658805-B2 | Fused polyheteroaromatic compound, organic thin film including the compound, and electronic device including the organic thin film | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2014-02-25 | — | — | US | disclosed |
| US-8658805-B2 | Fused polyheteroaromatic compound, organic thin film including the compound, and electronic device including the organic thin film | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2014-02-25 | — | — | US | disclosed |
| US-20130116447-A1 | FUSED POLYHETEROAROMATIC COMPOUND, ORGANIC THIN FILM INCLUDING THE COMPOUND, AND ELECTRONIC DEVICE INCLUDING THE ORGANIC THIN FILM | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2013-05-09 | — | — | US | disclosed |
| US-20130116447-A1 | FUSED POLYHETEROAROMATIC COMPOUND, ORGANIC THIN FILM INCLUDING THE COMPOUND, AND ELECTRONIC DEVICE INCLUDING THE ORGANIC THIN FILM | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116447-A1 | FUSED POLYHETEROAROMATIC COMPOUND, ORGANIC THIN FILM INCLUDING THE COMPOUND, AND ELECTRONIC DEVICE INCLUDING THE ORGANIC THIN FILM | EED, TMED7, PRDM7 | CYP2A6 3104/4885CHRNA7 1248/4885SMN1; SMN2 4578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.